ReviewJournal of asthma and allergy2016
Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances.
Review in Journal of asthma and allergy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Multidisciplinary management of type 2 inflammatory diseases.Multidisciplinary respiratory medicine · 2022Article
- Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches.Molecular biology reports · 2021Review
- Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost.World journal of otorhinolaryngology - head and neck surgery · 2020Review
- Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications.The Korean journal of internal medicine · 2020Review
- Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis.Allergy · 2020Article
- The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.International journal of molecular sciences · 2020Review
- NSAID-Exacerbated Respiratory Disease (NERD): From Pathogenesis to Improved Care.Frontiers in pharmacology · 2020Review
- Depression symptoms and quality of life among individuals with aspirin-exacerbated respiratory disease.The Journal of asthma : official journal of the Association for the Care of Asthma · 2019Article
- Current opinions for the management of asthma associated with ear, nose and throat comorbidities.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Eosinophil production of prostaglandin DThe Journal of allergy and clinical immunology · 2016Article
- A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes.Laryngoscope investigative otolaryngology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma and chronic rhinosinusitis are heterogeneous airway diseases of the lower and upper airways, respectively. Molecular and cellular studies indicate that these diseases can be categorized into unique endotypes, which have therapeutic implications. One such endotype is aspirin-exacerbated respiratory disease (AERD), which encompasses the triad of asthma, aspirin (or nonsteroidal anti-inflammatory drug) hypersensitivity, and nasal polyposis. AERD has unique pathophysiological features that distinguish it from aspirin-tolerant asthma and other forms of chronic rhinosinusitis. This review details molecular and cellular features of AERD and highlights current and future therapies that are based on these insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.